GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)

Market Cap	482.96B
Revenue (ttm)	37.05B
Net Income (ttm)	8.59B
Shares Out	n/a
EPS (ttm)	50.71
PE Ratio	56.21
Forward PE	n/a
Dividend	44.00 (1.57%)
Ex-Dividend Date	Nov 7, 2024

Volume	1,963,461
Average Volume	113,512
Open	2,865.00
Previous Close	2,846.60
Day's Range	2,855.10 - 3,148.00
52-Week Range	1,921.00 - 3,148.00
Beta	0.13
RSI	55.40
Earnings Date	May 13, 2025

About NSE:GLAXO

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease;...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1924
• Employees: 3,211
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GLAXO

Financial Performance

In 2023, NSE:GLAXO's revenue was 34.54 billion, an increase of 6.21% compared to the previous year's 32.52 billion. Earnings were 5.90 billion, a decrease of -3.39%.